Altium Wealth Management LLC boosted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 5.9% in the fourth quarter, HoldingsChannel reports. The fund owned 6,235 shares of the medical research company’s stock after purchasing an additional 345 shares during the quarter. Altium Wealth Management LLC’s holdings in Amgen were worth $1,503,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the stock. Balentine LLC raised its holdings in shares of Amgen by 36.1% in the third quarter. Balentine LLC now owns 181 shares of the medical research company’s stock worth $35,000 after buying an additional 48 shares during the last quarter. Belmont Capital LLC purchased a new position in shares of Amgen in the fourth quarter worth $36,000. Atwater Malick LLC purchased a new position in shares of Amgen in the third quarter worth $39,000. Strategic Blueprint LLC purchased a new position in shares of Amgen in the third quarter worth $45,000. Finally, Lenox Wealth Advisors LLC raised its holdings in shares of Amgen by 53.8% in the third quarter. Lenox Wealth Advisors LLC now owns 246 shares of the medical research company’s stock worth $48,000 after buying an additional 86 shares during the last quarter. 76.58% of the stock is owned by institutional investors.
A number of research analysts have issued reports on the stock. Bank of America assumed coverage on shares of Amgen in a report on Wednesday, October 16th. They issued a “neutral” rating and a $215.00 price target for the company. BidaskClub cut shares of Amgen from a “buy” rating to a “hold” rating in a report on Tuesday, December 31st. BMO Capital Markets raised their price target on shares of Amgen from $240.00 to $275.00 and gave the stock an “outperform” rating in a report on Thursday, January 9th. Cantor Fitzgerald reissued a “buy” rating and set a $255.00 target price on shares of Amgen in a report on Tuesday. Finally, Credit Suisse Group raised their target price on shares of Amgen from $235.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday, December 13th. Eleven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $235.22.
Shares of Amgen stock traded down $0.06 during trading on Friday, hitting $240.44. 622,372 shares of the company’s stock were exchanged, compared to its average volume of 1,906,640. The company has a debt-to-equity ratio of 2.54, a quick ratio of 2.59 and a current ratio of 2.89. The business has a 50-day simple moving average of $238.44 and a 200-day simple moving average of $209.08. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $244.99. The stock has a market capitalization of $142.60 billion, a price-to-earnings ratio of 16.70, a PEG ratio of 2.08 and a beta of 1.11.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.53 by $0.13. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.63 billion. Amgen had a net margin of 34.48% and a return on equity of 80.26%. The firm’s revenue was down 2.8% on a year-over-year basis. During the same quarter last year, the business earned $3.69 earnings per share. On average, equities analysts anticipate that Amgen, Inc. will post 14.58 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 14th will be given a dividend of $1.60 per share. This represents a $6.40 annualized dividend and a yield of 2.66%. The ex-dividend date of this dividend is Thursday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $1.45. Amgen’s dividend payout ratio (DPR) is currently 40.28%.
In related news, EVP Jonathan P. Graham sold 9,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $230.54, for a total transaction of $2,074,860.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $215.45, for a total transaction of $91,566.25. Following the sale, the director now owns 5,413 shares in the company, valued at approximately $1,166,230.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,162 shares of company stock worth $4,214,030. 0.25% of the stock is owned by company insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: Commodities
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.